Structure-Driven Developments of 26S Proteasome Inhibitors
Paweł Śledź1, Wolfgang Baumeister1
1Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany;
Abstract:
The 26S proteasome is a 2.5-MDa complex, and it operates at the executive end of the ubiquitin-proteasome pathway. It is a proven target for therapeutic agents for the treatment of some cancers and autoimmune diseases, and moreover, it has potential as a target of antibacterial agents. Most inhibitors, including all molecules approved for clinical use, target the 20S proteolytic core complex; its structure was determined two decades ago. Hitherto, efforts to develop inhibitors targeting the 19S regulatory particle subunits have been less successful. This is, in part, because the molecular architecture of this subcomplex has been, until recently, poorly understood, and high-resolution structures have been available only for a few subunits. In this review, we describe, from a structural perspective, the development of inhibitory molecules that target both the 20S and 19S subunits of the proteasome. We highlight the recent progress achieved in structure-based drug-discovery approaches, and we discuss the prospects for further improvement.
Insights
The 26S proteasome, a key cellular machine, is a therapeutic target for cancer and autoimmune diseases. This review details structural insights into developing inhibitors for both its 20S core and 19S regulatory particle.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- The 26S proteasome is a large molecular complex central to the ubiquitin-proteasome pathway.
- It is a validated therapeutic target for cancers and autoimmune diseases, with potential in antibacterial applications.
- Current therapeutic strategies primarily target the 20S core, whose structure has been known for two decades.
Purpose of the Study:
- To review the development of inhibitory molecules targeting both the 20S and 19S subunits of the 26S proteasome.
- To provide a structural perspective on proteasome inhibitor development.
- To highlight recent advancements in structure-based drug discovery for proteasome targets.
Main Methods:
- Structural analysis of proteasome subunits.
- Review of literature on proteasome inhibitors.
- Structure-based drug design approaches.
Main Results:
- The molecular architecture of the 19S regulatory particle has been poorly understood, hindering inhibitor development.
- Recent progress in structural biology has improved understanding of the 19S subunit.
- Structure-based drug discovery is advancing the development of inhibitors for both 20S and 19S proteasome targets.
Conclusions:
- Targeting the 19S regulatory particle presents a promising avenue for novel therapeutic agents.
- Continued structural studies and structure-based drug design will enhance the development of proteasome inhibitors.
- Further research holds potential for improved treatments for various diseases by targeting the 26S proteasome.
Related Concept Videos
01:17The Proteasome Structure
The proteasome is an...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
02:41Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...